|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...56789101112131415...9899» |
- Trial completion: RAD 0902: A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 19, 2016
P0, N=16, Completed, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed
- paracetamol / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Trial primary completion date: A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=3000, Active, not recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Jan 2017
- ||| Peglamda (peginterferon lamda 1) / Nanogen Biopharma
Trial completion, Phase classification, Trial primary completion date: The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients (clinicaltrials.gov) - Dec 15, 2016
P1a/1b, N=60, Completed, Sponsor: Nanogen Pharmaceutical Biotechnology Co., Ltd
Trial primary completion date: Sep 2016 --> Jan 2017 Recruiting --> Completed | Phase classification: P1 --> P1a/1b | Trial primary completion date: Jul 2014 --> Feb 2015
- Trial completion, Trial primary completion date: PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA) (clinicaltrials.gov) - Dec 15, 2016
P=N/A, N=20, Completed, Sponsor: dr. M.P. van den Tol MD PhD
Recruiting --> Completed | Phase classification: P1 --> P1a/1b | Trial primary completion date: Jul 2014 --> Feb 2015 Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2016
- Trial completion, Trial primary completion date, Metastases: Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies (clinicaltrials.gov) - Dec 9, 2016
P1, N=30, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed | Trial primary completion date: Jan 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jun 2016
- ||||||| Exviera (dasabuvir) / AbbVie
Trial completion: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease (clinicaltrials.gov) - Dec 8, 2016
P3, N=63, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jun 2016 Active, not recruiting --> Completed
- Trial primary completion date: Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC (clinicaltrials.gov) - Dec 7, 2016
P3, N=668, Recruiting, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Trial primary completion date: Aug 2016 --> Aug 2018
- norfloxacin / Generic mfg.
Enrollment change: A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome (clinicaltrials.gov) - Dec 7, 2016
P2, N=9, Completed, Sponsor: St. Michael's Hospital, Toronto
Trial primary completion date: Aug 2016 --> Aug 2018 N=20 --> 9
- pemetrexed / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer (clinicaltrials.gov) - Dec 7, 2016
P1/2, N=68, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=20 --> 9 Trial primary completion date: Feb 2008 --> Feb 2007
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=42, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Feb 2008 --> Feb 2007 Trial primary completion date: Oct 2009 --> Jan 2005
- docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=25, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Trial primary completion date: Oct 2009 --> Jan 2005 Trial primary completion date: Apr 2008 --> May 2004
- Trial initiation date: PACT CREATE 3: Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis (clinicaltrials.gov) - Dec 7, 2016
P=N/A, N=700, Not yet recruiting, Sponsor: VA Office of Research and Development
Trial primary completion date: Apr 2008 --> May 2004 Initiation date: Oct 2016 --> Mar 2017
- | pemetrexed / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer (clinicaltrials.gov) - Dec 6, 2016
P1/2, N=68, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Initiation date: Oct 2016 --> Mar 2017 Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer (clinicaltrials.gov) - Dec 6, 2016
P2, N=42, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | docetaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Metastases: Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer (clinicaltrials.gov) - Dec 6, 2016
P2, N=25, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Enrollment closed: MispheC: Efficacy Study of Intra-hepatic Administration of Therasphere (clinicaltrials.gov) - Dec 5, 2016
P2, N=41, Active, not recruiting, Sponsor: Center Eugene Marquis
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || Trial primary completion date: Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy (clinicaltrials.gov) - Dec 2, 2016
P4, N=1080, Active, not recruiting, Sponsor: Qidong Gaitianli Medicines Co., Ltd
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Dec 2016
- || entecavir / Generic mfg.
Trial primary completion date, Monotherapy: Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection (clinicaltrials.gov) - Dec 1, 2016
P=N/A, N=12500, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Dec 2016 --> Sep 2016
- ||| Trial completion: Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study) (clinicaltrials.gov) - Nov 30, 2016
P=N/A, N=370, Completed, Sponsor: University of British Columbia
Trial primary completion date: Dec 2016 --> Sep 2016 Active, not recruiting --> Completed
- TT-034 / Benitec
Enrollment closed, Enrollment change: Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034. (clinicaltrials.gov) - Nov 30, 2016
P1/2, N=9, Active, not recruiting, Sponsor: Tacere Therapeutics, Inc.
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=14 --> 9
- Phase classification, Trial primary completion date: Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization (clinicaltrials.gov) - Nov 30, 2016
P1, N=60, Recruiting, Sponsor: Washington University School of Medicine
Enrolling by invitation --> Active, not recruiting | N=14 --> 9 Phase classification: P=N/A --> P1 | Trial primary completion date: Oct 2016 --> Jun 2017
- Trial completion, Enrollment change, Trial primary completion date: The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis (clinicaltrials.gov) - Nov 29, 2016
P=N/A, N=106, Completed, Sponsor: University Health Network, Toronto
Phase classification: P=N/A --> P1 | Trial primary completion date: Oct 2016 --> Jun 2017 Recruiting --> Completed | N=168 --> 106 | Trial primary completion date: Sep 2017 --> May 2016
- Trial completion, Trial primary completion date, Surgery, Bariatric surgery: Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Nov 28, 2016
P=N/A, N=26, Completed, Sponsor: Sheba Medical Center
Recruiting --> Completed | N=168 --> 106 | Trial primary completion date: Sep 2017 --> May 2016 Not yet recruiting --> Completed | Trial primary completion date: Jul 2014 --> Aug 2016
- Enrollment change: Evaluation of Probiotics in the Treatment of Portal Hypertension (clinicaltrials.gov) - Nov 22, 2016
P=N/A, N=33, Completed, Sponsor: Pomeranian Medical University Szczecin
Not yet recruiting --> Completed | Trial primary completion date: Jul 2014 --> Aug 2016 N=50 --> 33
- Trial primary completion date: Mother-to-child Hepatitis D Transmission (clinicaltrials.gov) - Nov 22, 2016
P=N/A, N=40, Recruiting, Sponsor: Hopital Lariboisière
N=50 --> 33 Trial primary completion date: Jul 2016 --> Jul 2017
- Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy (clinicaltrials.gov) - Nov 22, 2016
P4, N=37, Completed, Sponsor: Hopital Lariboisière
Trial primary completion date: Jul 2016 --> Jul 2017 Recruiting --> Completed | N=25 --> 37 | Initiation date: Nov 2011 --> Jul 2012 | Trial primary completion date: Jul 2016 --> Jan 2016
- Isentress (raltegravir) / Merck (MSD)
Enrollment closed, Enrollment change, Trial initiation date, Trial primary completion date: STERAL: Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection (clinicaltrials.gov) - Nov 22, 2016
P4, N=45, Active, not recruiting, Sponsor: Juan Mac
Recruiting --> Completed | N=25 --> 37 | Initiation date: Nov 2011 --> Jul 2012 | Trial primary completion date: Jul 2016 --> Jan 2016 Not yet recruiting --> Active, not recruiting | N=96 --> 45 | Initiation date: Nov 2013 --> Nov 2014 | Trial primary completion date: Jan 2015 --> Mar 2017
- L-ornithine-L-aspartate / Generic mfg.
Enrollment closed: HEAL: L-ornithine L-aspartate in Overt Hepatic Encephalopathy (clinicaltrials.gov) - Nov 17, 2016
P4, N=200, Active, not recruiting, Sponsor: Dayanand Medical College and Hospital
Not yet recruiting --> Active, not recruiting | N=96 --> 45 | Initiation date: Nov 2013 --> Nov 2014 | Trial primary completion date: Jan 2015 --> Mar 2017 Recruiting --> Active, not recruiting
- Euvax B (recombinant hepatitis B vaccine) / LG Chem
Enrollment closed: Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda (clinicaltrials.gov) - Nov 17, 2016
P4, N=132, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Enrollment change, Trial withdrawal, Metastases: Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Nov 15, 2016
P1/2, N=0, Withdrawn, Sponsor: Philipps University Marburg Medical Center
Recruiting --> Active, not recruiting N=18 --> 0 | Recruiting --> Withdrawn
- Intron A (interferon ?-2b) / Merck (MSD), Biogen
Phase classification: Differences in Evoked Intracellular Interferon Signaling Pathways Using Single Cell Phosphoprotein Profiling (clinicaltrials.gov) - Nov 15, 2016
P1, N=22, Completed, Sponsor: University of North Carolina, Chapel Hill
N=18 --> 0 | Recruiting --> Withdrawn Phase classification: P=N/A --> P1
- Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Trial completion, Enrollment change, Trial primary completion date: RIFSYS: Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy (clinicaltrials.gov) - Nov 14, 2016
P4, N=38, Completed, Sponsor: King's College Hospital NHS Trust
Phase classification: P=N/A --> P1 Recruiting --> Completed | N=50 --> 38 | Trial primary completion date: Oct 2015 --> Jun 2016
- Trial primary completion date: LIPROCES: Influence of Probiotics Administration Before Liver Resection in Liver Disease (clinicaltrials.gov) - Nov 10, 2016
P=N/A, N=64, Recruiting, Sponsor: University Hospital, Rouen
Recruiting --> Completed | N=50 --> 38 | Trial primary completion date: Oct 2015 --> Jun 2016 Trial primary completion date: Sep 2016 --> Jan 2017
- |||| tenofovir disoproxil fumarate / Generic mfg., entecavir / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir (clinicaltrials.gov) - Nov 9, 2016
P4, N=60, Completed, Sponsor: Korea University
Trial primary completion date: Sep 2016 --> Jan 2017 Recruiting --> Completed | N=110 --> 60 | Trial primary completion date: Dec 2014 --> Dec 2015
- Trial completion, Trial primary completion date: Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC) (clinicaltrials.gov) - Nov 8, 2016
P=N/A, N=26, Completed, Sponsor: Angiodynamics, Inc.
Recruiting --> Completed | N=110 --> 60 | Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jan 2013
- Trial completion, Trial primary completion date, Metastases: Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors (clinicaltrials.gov) - Nov 7, 2016
P=N/A, N=9, Completed, Sponsor: University of Miami
Active, not recruiting --> Completed | Trial primary completion date: Oct 2011 --> Jan 2013 Trial primary completion date: Apr 2017 --> Oct 2016 | Recruiting --> Completed
- Cyramza (ramucirumab) / Eli Lilly
Trial completion, Metastases: A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer (clinicaltrials.gov) - Nov 7, 2016
P1b, N=9, Completed, Sponsor: Eli Lilly and Company
Trial primary completion date: Apr 2017 --> Oct 2016 | Recruiting --> Completed Active, not recruiting --> Completed
- ledipasvir/sofosbuvir / Generic mfg.
Trial primary completion date: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Nov 2, 2016
P4, N=1000, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Trial primary completion date: Jun 2017 --> Jun 2016
- | Trial initiation date: Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 2, 2016
P3, N=812, Recruiting, Sponsor: Sun Yat-sen University
Trial primary completion date: Jun 2017 --> Jun 2016 Initiation date: Feb 2012 --> Jan 2011
- | Ibrance (palbociclib) / Pfizer
Trial completion: A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib (clinicaltrials.gov) - Nov 2, 2016
P1, N=28, Completed, Sponsor: Pfizer
Initiation date: Feb 2012 --> Jan 2011 Recruiting --> Completed
- ledipasvir/sofosbuvir / Generic mfg.
Enrollment closed: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia (clinicaltrials.gov) - Nov 1, 2016
P4, N=1000, Active, not recruiting, Sponsor: National Institutes of Health Clinical Center (CC)
Recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- trimethoprim/sulfamethoxazole / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: VSL#3 and Spontaneous Bacterial Peritonitis (clinicaltrials.gov) - Oct 28, 2016
P2, N=10, Terminated, Sponsor: Nottingham University Hospitals NHS Trust
Enrolling by invitation --> Active, not recruiting N=51 --> 10 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Oct 2014; Unable to obtain QP release certification from the manufacturer (VSL3) for shipment of IMP
- lamivudine HBV / Generic mfg., adefovir dipivoxil / Generic mfg.
Trial completion: TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA (clinicaltrials.gov) - Oct 28, 2016
P4, N=171, Completed, Sponsor: Keimyung University Dongsan Medical Center
N=51 --> 10 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Oct 2014; Unable to obtain QP release certification from the manufacturer (VSL3) for shipment of IMP Active, not recruiting --> Completed
- ||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Enrollment change: Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine (clinicaltrials.gov) - Oct 27, 2016
P2, N=403, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=219 --> 403
- Trial completion: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=1927, Completed, Sponsor: University Hospital, Geneva
N=219 --> 403 Active, not recruiting --> Completed
- Pegasys (pegylated interferon α -2a) / Roche, Roferon A (recombinant interferon alfa-2a) / Roche
Trial termination, Trial primary completion date: An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a) (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=45, Terminated, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Mar 2015; Terminated due to financial reasons.
- Enrollment change, Trial withdrawal, Trial primary completion date: Direct Peritoneal Resuscitation Plus Conventional Resuscitation (clinicaltrials.gov) - Oct 27, 2016
P4, N=0, Withdrawn, Sponsor: University of Louisville
Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Mar 2015; Terminated due to financial reasons. N=108 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2015 --> May 2014
- Biomarker, Trial primary completion date: Development of a Novel Biomarker for Liver Fibrosis (clinicaltrials.gov) - Oct 27, 2016
P=N/A, N=125, Recruiting, Sponsor: University of California, Los Angeles
N=108 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jan 2015 --> May 2014 Trial primary completion date: Dec 2016 --> Mar 2017
- Pegintron/Rebetol Combo Pack (peginterferon alfa-2b + ribavirin) / Merck (MSD), ViraferonPeg (peginterferon-?-2b) / Merck (MSD)
Trial completion: HCV Treatment in HIV Co-Infected Patients in Asia (clinicaltrials.gov) - Oct 27, 2016
P4, N=188, Completed, Sponsor: amfAR, The Foundation for AIDS Research
Trial primary completion date: Dec 2016 --> Mar 2017 Active, not recruiting --> Completed
- Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Enrollment change, Trial completion date, Trial withdrawal: Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism (clinicaltrials.gov) - Oct 27, 2016
P4, N=0, Withdrawn, Sponsor: University of Vermont
Active, not recruiting --> Completed N=240 --> 0 | Trial completion date: Jun 2014 --> Jul 2011 | Terminated --> Withdrawn